Oxford BioDynamics Awarded US FNIH Grant to Apply EpiSwitch® Immune Health Test for Improved Prediction of Patient Response to Immune Checkpoint Inhibitor (ICI) Cancer Therapies
Retrieved on:
Tuesday, August 31, 2021
Biotechnology, Pharmaceutical, Health, ICIS, Company, OBD, NIBR, Sanofi, Associate, BioRxiv, PD-1, COVID, Blood, Food and Drug Administration, Johns Hopkins, Cancer, Prognosis, PD-L1, Rheumatoid arthritis, LDT, Biomarker, AbbVie, Boehringer Ingelheim, N8 Research Partnership, RFA, COVID-19, Janssen, National Cancer Institute, National, Autoimmunity, IO, AIM, Foundation, Genomics, NCI, Patient, GlaxoSmithKline, Amgen, Epidemiology, US Foods, NIH, Bristol Myers Squibb, FNIH, Precision medicine, PACT, Veni, vidi, vici, Oncology, Classification, Technology, ICI, Pharmaceutical industry, Vaccine, Medical imaging
PACT seeks to provide a systematic approach to cancer biomarker investigation in clinical trials by supporting development of standardized assays.
Key Points:
- PACT seeks to provide a systematic approach to cancer biomarker investigation in clinical trials by supporting development of standardized assays.
- Unfortunately, a similar number will experience significant and sometime fatal side effects when these therapies are used[2].
- The test, which is a predictive diagnostic of likely response in cancer patients considered for monotherapy treatment with immune checkpoint inhibitors, has been in full development since 2018.
- The project will further validate this first-generation immune health assay for predicting response as well as monitoring resistance to ICI monotherapies.